- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00451516
St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety commonly occurs, it is conceivable that a combination of an established antidepressant agent such as SJW and an established anxiolytic agent such as kava may effectively treat MDD presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid anxiety, than by the individual substances alone. Determination of this is not addressed in this study due to limitations of time and resources. The determination of the strength of the SJW-kava combination will be ascertained by comparing similar trials using SJW and kava mono-therapy in addressing MDD and GAD.
The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- RBWH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Any person male or female aged 18-65 presenting with a diagnosis of unipolar depression confirmed by CIDI auto (quantified by BDI) and an anxiety score on the DASS of 8 or above i.e. the mean (quantified also by BAI)
Exclusion criteria:
- Psychotic/ Bipolar illness
- Current or < 6 month significant suicidal ideation
- Diagnosed hepato-biliary disease/inflammation
- Current or < 6 month substance abuse disorder including alcohol
- Current or < 12 month use of kava, St. John's wort,
- Current or < 1 month of synthetic antidepressants or benzodiazepines
- Previous reaction to kava or St. John's wort
Medications that maybe pharmacokinetically altered via St. John's wort including:
- Amitriptyline anti-coagulants e.g. phenprocoumon, warfarin,
- Anti-fugals e.g. voriconazole,
- Anti-histamines e.g. fexofenadine,
- Benzodiazepines e.g. alprazolam,
- Chemotherapeutics e.g. irinotecan, digoxin, HIV medication (anti-retrovirals), * Immunosuppressants e.g. cyclosporine, methadone, OCP,
- Statins e.g. simvastatin, warfarin (Henderson 2002; Izzo 2004).
- However this interactions are based on case studies and theoretical interactions and are regarded to be induced by hyperforin (a constituent of St. John's wort); low or non-standardised hyperforin preparations are regarded to not induce drug interactions as little induction of P-glycoprotein and CYP P450 enzymes occurs (Madabushi et al. 2006). Although in vitro studies have confirmed that kava and the isolated kavalactones modulate certain CYP 450 enzymes, no documented evidence of human kava-drug pharmacokinetic interactions exists (Mathews, Etheridge & Black 2002; Singh 2005)
- Seeing a psychologist or counsellor currently or in the previous month.
- Non-English speakers.
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
BDI II
|
BAI
|
DASS
|
Secondary Outcome Measures
Outcome Measure |
---|
WHOQOL
|
Daily Mood Monitoring Form
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jerome Sarris, BHSc, The University of Queensland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006000925
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety Disorders
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Loma Linda UniversityCompletedParental/Caregiver Anxiety | Child's AnxietyUnited States
Clinical Trials on Herbal medicine (St. John's wort and Kava)
-
Ceres Heilmittel AGUniversity of ZurichCompleted
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of Southern DenmarkCompleted
-
Mayo ClinicCompletedIrritable Bowel SyndromeUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous ConditionUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedBreast Cancer | Hot FlashesUnited States
-
National Center for Complementary and Integrative...Completed
-
National Center for Complementary and Integrative...CompletedObsessive Compulsive DisorderUnited States
-
National Center for Complementary and Integrative...CompletedAnxiety Disorders | Mental HealthUnited States
-
National Center for Complementary and Integrative...CompletedAttention Deficit Hyperactivity DisorderUnited States